Search Result

Results for "

Parkinson disease (PD)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (3) Adenosine Receptor (1) Adrenergic Receptor (3) Akt (2) Amyloid-β (1) Apoptosis (5) Aryl Hydrocarbon Receptor (1) Autophagy (3) Bcr-Abl (5) Biochemical Assay Reagents (1) c-Met/HGFR (1) Calcium Channel (1) Caspase (3) CD28 (2) COMT (4) COX (2) Cytochrome P450 (1) Dopamine Receptor (22) Drug Derivative (1) Drug Metabolite (3) Endogenous Metabolite (4) ERK (2) FAAH (1) GABA Receptor (1) Glycosidase (3) GPR55 (1) HDAC (1) IAP (1) iGluR (3) Interleukin Related (3) Isotope-Labeled Compounds (3) JNK (3) Keap1-Nrf2 (4) LRRK2 (8) mGluR (6) Mitophagy (3) MMP (1) MNK (1) Monoamine Oxidase (17) Neurotensin Receptor (1) Nuclear Hormone Receptor 4A/NR4A (1) p38 MAPK (2) PGE synthase (2) Prostaglandin Receptor (1) PROTACs (3) Reactive Oxygen Species (ROS) (7) Reference Standards (9) RET (1) Sigma Receptor (1) SOD (1) Survivin (1) Tau Protein (2) Trace Amine-associated Receptor (TAAR) (1) Transferrin Receptor (1) Tyrosine Hydroxylase (1) ULK (1) α-synuclein (22)
By Research Areas:	Cancer (14) Endocrinology (3) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (112)
Click Chemistry:	Alkynes (3)

115

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: PD-1/PD-L1

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-B1081A

Oxidopamine hydrobromide Maximum Cited Publications 41 Publications Verification 6-Hydroxydopamine hydrobromide; 6-OHDA hydrobromide	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrobromide is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrobromide is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrobromide promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrobromide can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-B1081

Oxidopamine hydrochloride Maximum Cited Publications 41 Publications Verification 6-Hydroxydopamine Hydrochloride	Dopamine Receptor Autophagy Mitophagy COX PGE synthase Interleukin Related p38 MAPK Apoptosis Caspase	Neurological Disease Cancer
Oxidopamine (6-OHDA) hydrochloride is an antagonist of the neurotransmitter dopamine. Oxidopamine hydrochloride is a widely used neurotoxin and selectively destroys dopaminergic neurons. Oxidopamine hydrochloride promotes COX-2 activation, leading to PGE₂ synthesis and pro-inflammatory cytokine IL-1β secretion. Oxidopamine hydrochloride can be used for the research of Parkinson’s disease (PD), attention-deficit hyperactivity disorder (ADHD), and Lesch-Nyhan syndrome .

HY-17355

Pramipexole dihydrochloride 10+ Cited Publications	Dopamine Receptor	Neurological Disease
Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D₂, D₃ and D₄ receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-B0410

Pramipexole 10+ Cited Publications	Dopamine Receptor	Neurological Disease
Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D₂, D₃ and D₄ receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-75502

Rotigotine 3 Publications Verification N-0923; (-)-N 0437	Dopamine Receptor Adrenergic Receptor 5-HT Receptor	Neurological Disease Endocrinology
Rotigotine is a potent dopamine receptor agonist with K_i values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research .

HY-110125

ML-193 1 Publications Verification CID 1261822	GPR55	Neurological Disease
ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC₅₀ of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats .

HY-W342604

N-Acetylputrescine 1 Publications Verification NAP	Endogenous Metabolite	Neurological Disease Cancer
N-Acetylputrescine is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD) .

HY-147976

Glucocerebrosidase-IN-1	Glycosidase	Neurological Disease Metabolic Disease
Glucocerebrosidase-IN-1 (compound 11a) is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC₅₀ of 29.3 μM and a K_i of 18.5 μM. Glucocerebrosidase-IN-1 can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .

HY-124729

BL-918 3 Publications Verification	ULK Autophagy	Neurological Disease
BL-918 is an orally active UNC-51-like kinase 1 (ULK1) activator with an EC₅₀ of 24.14 nM. BL-918 exerts its cytoprotective autophagic effect by targeting ULK complex. BL-918 has the potential for Parkinson’s disease (PD) treatment .

HY-148794

Risvodetinib IkT-148009	c-Met/HGFR Bcr-Abl	Neurological Disease Cancer
Risvodetinib (IkT-148009) is an orally active, selective and brain-penetrant protein tyrosine kinase inhibitor, displaying excellent target efficacy against c-Abl1, c-Abl2/Arg with IC₅₀ values of 33 nM, 14 nM, respectively. Risvodetinib suppresses c-Abl activation and substantially protects dopaminergic neurons from degeneration in mouse models of both inherited and sporadic Parkinson’s disease (PD), which is promising for research in the field of PD .

HY-13993

Ro 25-6981 5+ Cited Publications	iGluR	Neurological Disease
Ro 25-6981 is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 has the potential for the research of parkinson's disease (PD) .

HY-12282

GNE-9605	LRRK2	Neurological Disease
GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC₅₀ value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) .

HY-120475

PBT434 2 Publications Verification ATH434	α-synuclein	Neurological Disease
PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD) .

HY-113100

N-Acetylputrescine hydrochloride 1 Publications Verification	Endogenous Metabolite	Neurological Disease Cancer
N-Acetylputrescine hydrochloride is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine hydrochloride may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine hydrochloride can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine hydrochloride can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD) .

HY-13993A

Ro 25-6981 Maleate 5+ Cited Publications	iGluR	Neurological Disease
Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD) .

HY-155150

JH-XII-03-02	LRRK2 PROTACs	Cancer
JH-XII-03-02 is a potent and selective LRRK2 PROTAC degrader. JH-XII-03-02 can be used for parkinson's Disease (PD) research .

HY-116016

Etilevodopa L-DOPA ethyl ester; Levodopa ethyl ester	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-131678

Palmitoyl serotonin PA-5HT	FAAH	Neurological Disease
Palmitoyl serotonin is a hybrid molecule patterned after arachidonoyl serotonin, antagonist of FAAH. Palmitoyl serotonin inhibits L-3,4-dihydroxyphenylalanine (HY-N0304) induced abnormal involuntary movements. Palmitoyl serotonin has the potential for the research of parkinson's disease (PD) .

HY-B0410A

Pramipexole dihydrochloride hydrate 10+ Cited Publications	Dopamine Receptor	Neurological Disease
Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D₂, D₃ and D₄ receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-108237

Naxagolide (+)-PHNO; Dopazinol	Dopamine Receptor	Neurological Disease
Naxagolide ((+)-PHNO; Dopazinol) is a potent dopamine D2 (Dopamine Receptor) agonist. Naxagolide has the potential for the research of parkinson's disease (PD) .

HY-148867

UCM-1306	Dopamine Receptor	Neurological Disease
UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD) .

HY-120475A

PBT434 mesylate 2 Publications Verification ATH434 mesylate	α-synuclein	Neurological Disease
PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD) .

HY-147319

RTI-7470-44	Trace Amine-associated Receptor (TAAR)	Neurological Disease
RTI-7470-44 is a potent, selective and blood-brain barrier (BBB) penetrant human trace amine-associated receptor subtype 1 (hTAAR1) antagonist with an IC₅₀ value of 8.4 nM and a K_i value of 0.3 nM. RTI-7470-44 has moderate metabolic stability, and a favorable preliminary off-target profile. RTI-7470-44 can increase the spontaneous firing rate of mouse ventral tegmental area (VTA) dopaminergic neurons. RTI-7470-44 can be used for researching schizophrenia, agent addiction, and Parkinson’s disease (PD) .

HY-120553

B-355252 1 Publications Verification	Apoptosis	Neurological Disease
B355252, a phenoxy thiophene sulfonamide small molecule, is a potent NGF receptor agonist. B355252 potentiates NGF-induced neurite outgrowth. B355252 protects ischemic neurons from neuronal loss by attenuating DNA damage, reducing ROS production and the LDH level, and preventing neuronal apoptosis. B355252 has anti-apoptotic effects in glutamate-induced excitotoxicity, as well as in a murine hippocampal cell line (HT22) model of Parkinson disease (PD) .

HY-150058

Bocconoline	Others	Neurological Disease
Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD) .

HY-14417

VU0155041	mGluR	Neurological Disease
VU0155041 is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC₅₀s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD) .

HY-175352

Nurr1 agonist 14	Nuclear Hormone Receptor 4A/NR4A SOD IAP Survivin Calcium Channel	Neurological Disease
Nurr1 agonist 14 (Compound 32) is a Nurr1 agonist with an EC₅₀ of 0.09  μM for Nurr1. Nurr1 agonist 14 has significant neuroprotective activity with no influence of residual DHODH inhibition. Nurr1 agonist 14 upregulates neuroprotective genes including SOD2, SESN3, BIRC5, XIAP, FLRT2 and CRMP4 in dopaminergic neurons. Nurr1 agonist 14 can be used for neurodegenerative diseases such as Alzheimer′s disease (AD), Parkinson′s disease (PD) and multiple sclerosis (MS) research .

HY-160426

Gcase activator 3	Glycosidase	Neurological Disease
Gcase activator 3 (compound 9Q) is a glucosidase (Glucosidase, GCase) activator that can partially stabilize GCase and increase its activity. Gcase activator 3 reduces mutant GCase protein misfolding and degradation in fibroblasts and dopaminergic midbrain neurons. Gcase activator 3 can be used in the study of Parkinson's disease (PD) and related synucleinopathies .

HY-144634

DDO-7263 1 Publications Verification	Keap1-Nrf2	Neurological Disease Inflammation/Immunology
DDO-7263, a 1,2,4-Oxadiazole derivative, is a potent Nrf2-ARE activator. DDO-7263 upregulates Nrf2 through binding to Rpn6 to block the assembly of 26S proteasome and the subsequent degradation of ubiquitinated Nrf2. DDO-7263 induces Nrf2 translocation into the nucleus. DDO-7263 inhibits of NLRP3 inflammasome activation. DDO-7263 exerts anti-inflammatory activity and has the potential for neurodegenerative diseases research, such as Parkinson's disease (PD) .

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-D2871

DAyne	Biochemical Assay Reagents	Neurological Disease
DAyne is a Dopamine (DA)-mimetic probe. DAyne covalently binds to proteins modified by dopamine oxidation products (e.g., dopaquinone, DQ) to form adducts. DAyne is promising for research of Parkinson’s disease (PD), particularly neurotoxicity, protein modification, and related pathways (e.g., endoplasmic reticulum stress, cytoskeletal instability) caused by dopamine dysregulation .

HY-P3140A

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-112855

PF-06454589	LRRK2	Neurological Disease
PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC₅₀ values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06447475 can be used for parkinson's disease (PD) research .

HY-175840

TAU-IN-5	Tau Protein	Neurological Disease
TAU-IN-5 (compound 13) is a TAU protein inhibitor with an EC50 of 0.81 μM. TAU-IN-5 inhibits the formation of tau (2N4R isoform) oligomers and reduces the formation of tau dimers. TAU-IN-5 can be used in the study of Alzheimer's disease (AD) and Parkinson's disease (PD) .

HY-120419

PF9601N	Monoamine Oxidase	Neurological Disease
PF9601N, an monoamine oxidase B (MAO-B) inhibitor, possesses neuroprotective properties in several in vitro and in vivo models of Parkinson's disease (PD). PF9601N can be used for the research of neurodegenerative diseases mediated by excitotoxicity . PF9601N is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-157308

α-Synuclein inhibitor 10	α-synuclein	Neurological Disease
α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC₅₀ value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .

HY-151430

Nrf2/HO-1 activator 1	Keap1-Nrf2 ERK Akt JNK Reactive Oxygen Species (ROS)	Neurological Disease
Nrf2/HO-1 activator 1 (Compound 24) is a potent Nrf2/HO-1 activator, neuroprotective agent. Nrf2/HO-1 activator 1 shows neuroprotective and antioxidant activities. Nrf2/HO-1 activator 1 can be used in Parkinson's disease (PD) research .

HY-17355S1

Pramipexole-d5 dihydrochloride	Isotope-Labeled Compounds Dopamine Receptor	Neurological Disease
Pramipexole-d₅ dihydrochloride is deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-148353

PF-06455943	LRRK2	Neurological Disease
PF-06455943 is a leucine rich repeat kinase 2 (LRRK2) inhibitor with IC₅₀ value of 3 nM. PF-06455943 also is a PET radioligand. PF-06455943 can be used for the research of ADME/neuro PK characterization and Parkinson disease (PD) .

HY-147976A

Glucocerebrosidase-IN-1 hydrochloride	Glycosidase	Neurological Disease
Glucocerebrosidase-IN-1 (compound 11a) hydrochloride is a potent and selective GCase (glucocerebrosidase) inhibitor, with an IC₅₀ of 29.3 μM and a K_i of 18.5 μM. Glucocerebrosidase-IN-1 hydrochloride can be used for the research of Gaucher disease (GD) and Parkinson’s disease (PD) .

HY-107505A

CBiPES	mGluR	Neurological Disease
CBiPES is a potent mGlu2 positive allosteric modulator with an EC₅₀ value of 92.8 nM. CBiPES attenuates stress-induced hyperthermia and Phencyclidine-induced hyperlocomotor activity. CBiPES can be used for research of neurological diseases, such as Parkinson's disease (PD) .

HY-163172

Miro1 Reducer	Mitophagy	Neurological Disease
Miro1 Reducer is a small molecule that can repair this defect of Miro1 in Parkinson's disease (PD) fibroblasts. Miro1 Reducer reduces the delayed mitophagy phenotype in PD fibroblasts. Miro1 Reducer reduces Miro1 protein levels in dose-dependent manner (IC₅₀ = 7.8 mM) .

HY-151388

hMAO-B/MB-COMT-IN-1	Monoamine Oxidase COMT	Neurological Disease
hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor (IC₅₀s: 2.5 μΜ for hMAO-B, 3.84 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-1 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-1 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD) .

HY-152671

hMAO-B-IN-4	Monoamine Oxidase	Neurological Disease
hMAO-B-IN-4 (compound B10) is a selective, reversible and blood–brain barrier (BBB) penetrable human monoamine oxidase-B (hMAO-B) inhibitor with an IC₅₀ value and a K_i value of 0.067 and 0.03 μM, respectively. hMAO-B-IN-4 inhibits hMAO-A with an IC₅₀ value of 33.82 μM. hMAO-B-IN-4 can be used for Alzheimer’s disease (AD) and Parkinson’s disease (PD) research .

HY-W628136

MAO-B-IN-47	Monoamine Oxidase	Neurological Disease
MAO-B-IN-47 is a selective monoamine oxidase B (MAO-B) inhibitor with a K_i of 875 nM. MAO-B-IN-47 shows an IC₅₀ >100 μM for SH-SY5Y cells. MAO-B-IN-47 shows neuroprotective effect in 6-OHDA-treated SH-SY5Y cells. MAO-B-IN-47 can be used for the research of neurological disease, such as Parkinson’s disease (PD) .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-116016A

Etilevodopa hydrochloride L-DOPA ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-178920

α-Synuclein-IN-17	α-synuclein	Neurological Disease
α-Synuclein-IN-17 (Compound 10) is an α-Synuclein inhibitor, with an IC₅₀ value of 9 μM. α-Synuclein-IN-17 exhibits potent inhibitory activity against both in-vitro assembled asyn fibrils and LBD brain tissue-amplified asyn fibrils. α-Synuclein-IN-17 can be used for the study of Parkinson's disease (PD) and Lewy Body Disease (LBD) .

HY-163145

α-Synuclein inhibitor 11	α-synuclein	Neurological Disease
α-Synuclein inhibitor 11 (compound 1) is a selective α-synuclein (α-syn) oligomer formation inhibitor. α-Synuclein inhibitor 11 does not inhibits tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synuclein inhibitor 11 can be used for Parkinson's disease (PD) research .

HY-120826

A2AAR/hMAO-B-IN-1	Monoamine Oxidase Adenosine Receptor	Neurological Disease
A2AAR/hMAO-B-IN-1 (compoudn 17) is a non-xanthine dual-target inhibitor targeting the A2A adenosine receptor (A2AAR) (IC₅₀: 34.9 nM) andMAO-B (Ki: 39.5 nM, human). A2AAR/hMAO-B-IN-1 inhibits A2AAR-induced cAMP accumulation and exhibits competitive, reversible inhibition of MAO-B. A2AAR/hMAO-B-IN-1 can be used in the study of neurodegenerative diseases such as Parkinson's disease (PD) .

Cat. No.	상품명

HY-L085

Anti-Parkinson's Disease Compound Library

2,085 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 2,085 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

HY-L028

CNS-Penetrant Compound Library

1,096 compounds

The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneﬁcial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.

MCE offers a unique collection of 1,096 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

HY-L086

Neurodegenerative Disease-related Compound Library

3,545 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 3,545 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

HY-L134

Anti-Aging Natural Product Library

193 compounds

Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases.

Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 193 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

HY-L010

MAPK Compound Library

1,063 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 1,063 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

Cat. No.	상품명	Target	Research Area

HY-P4704A

α-Synuclein (61-95) (human) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P3140A

α-Synuclein (61-75) TFA	α-synuclein	Neurological Disease
α-Synuclein (61-75) TFA is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P3140

α-Synuclein (61-75)	α-synuclein	Neurological Disease
α-Synuclein (61-75) is the 61-75 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-Synuclein is a potential biomarker for Parkinson's disease (PD) .

HY-P4704

α-Synuclein (61-95) (human)	α-synuclein	Neurological Disease
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD) .

HY-P5046

α-Synuclein (71-82) (human)	α-synuclein	Neurological Disease
α-Synuclein (71-82) (human) is the 71-82 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5044

α-Synuclein (45-54) (human)	α-synuclein	Neurological Disease
α-Synuclein (45-54) (human) is the 45-54 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD) .

HY-P5041

α-Synuclein (34-45) (human)	α-synuclein	Neurological Disease
α-Synuclein (34-45) (human) is the 34-45 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a Parkinson's disease (PD) biomarker .

HY-149941

hNTS1R agonist-1	Neurotensin Receptor	Neurological Disease
hNTS1R agonist-1 (Compound 10) is a BBB permeable hNTS1R full agonist (K_i: 6.9 nM) . hNTS1R agonist-1 increases motor function and memory in a mouse model of Parkinson's disease (PD). hNTS1R agonist-1 is a Neurotensin(8-13) analog and is a neuroprotective agent .

Cat. No.	상품명	Target	Research Area	Image

HY-P991380

TXB4	Transferrin Receptor	Neurological Disease
TXB4 is a brain-permeable human monoclonal antibody (mAb) targeting CD71. TXB4 prevents 6-OHDA-induced death of TH-positive neurons in the SNc in a 6-OHDA mouse model of Parkinson's disease (PD). TXB4 can be used in neurodegenerative diseases, acute brain and spinal cord injury, and depression research .

HY-P990793

Anti-Mouse CD28 Antibody (D665)	CD28	Neurological Disease Inflammation/Immunology Cancer
Anti-Mouse CD28 Antibody (D665) is a mouse-derived agonistic IgG1 κ type antibody, targeting to mouse CD28. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for the researches of neurological disease, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD) .

HY-P99123A

Anti-Mouse CD28 (LALA-PG) Antibody (D665)	CD28	Neurological Disease Inflammation/Immunology Cancer
Anti-Mouse CD28 (LALA-PG) Antibody (D665) is an anti-mouse CD28 IgG2a monoclonal antibody. Anti-Mouse CD28 (LALA-PG) Antibody (D665) is a chimeric antibody of the original D665 antibody (HY-P990793). Anti-Mouse CD28 (LALA-PG) Antibody (D665) contains the LALA-PG mutation region. Anti-Mouse CD28 Antibody (D665) induces the activation of T cells. Anti-Mouse CD28 Antibody (D665) can be used for research on neurological conditions, inflammation, immunology and cancer, such as Parkinson disease (PD), arthritis and graft-versus-host disease (GVHD).

Cat. No.	상품명	Category	Target	Chemical Structure

HY-W342604

N-Acetylputrescine 1 Publications Verification NAP	Structural Classification Alkaloids Human Gut Microbiota Metabolites Neurological Disease Classification of Application Fields Other Alkaloids Endogenous metabolite Disease Research Fields Source Classification Cancer	Endogenous Metabolite
N-Acetylputrescine is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD) .

HY-113100

N-Acetylputrescine hydrochloride 1 Publications Verification	Natural Products Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
N-Acetylputrescine hydrochloride is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine hydrochloride may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine hydrochloride can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine hydrochloride can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD) .

HY-113366

Prostaglandin J2 PGJ2	Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Prostaglandin Receptor Endogenous Metabolite
Prostaglandin J2 (PGJ2), an endogenous metabolite of Prostaglandin D2 (PGD2; HY-101988), is a potent PGD2 receptor (DP) agonist with K_is of 0.9 nM and 6.6 nM for hDP and hCRTH2, respectively. Prostaglandin J2 stimulates intracellular cyclic AMP production with an EC₅₀ value of 1.2 nM. Prostaglandin J2 induces oxidative stress and neuronal apoptosis. Prostaglandin J2 induces the accumulation/aggregation of ubiquitinated (Ub) proteins. Prostaglandin J2 is highly neurotoxic and potentially contributes to many neurodegenerative conditions, including Alzheimer's (AD) and Parkinson's diseases (PD) .

HY-150058

Bocconoline	Alkaloids Bocconia pearcei Plants Isoquinoline Alkaloids Papaveraceae Source Classification	Others
Bocconoline is a potent early endosome antigen 1 (EEA1) inhibitor. Bocconoline can be isolated from Macleaya cordata. Bocconoline can be used for the research of Parkinson’s disease (PD) .

HY-113100R

N-Acetylputrescine hydrochloride (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
N-Acetylputrescine hydrochloride (Standard) is the analytical standard for N-Acetylputrescine hydrochloride (HY-113100). This product is intended for research and analytical applications. N-Acetylputrescine hydrochloride is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine hydrochloride may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine hydrochloride can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine hydrochloride can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD) .

HY-W014701R

1,4-Dihydroxy-2-naphthoic acid (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source Classification	Reference Standards Aryl Hydrocarbon Receptor Cytochrome P450 Apoptosis Interleukin Related
1,4-Dihydroxy-2-naphthoic acid (Standard) is the analytical standard for 1,4-Dihydroxy-2-naphthoic acid (HY-W014701). 1,4-Dihydroxy-2-naphthoic acid is an orally active aryl hydrocarbon receptor (AhR) agonist and a bifidogenic growth stimulator. 1,4-Dihydroxy-2-naphthoic acid can improve the motor dysfunction in parkinson's disease (PD) model through AhR-dependent and -independent pathways. 1,4-Dihydroxy-2-naphthoic acid exerts anti-inflammatory effects by regulating the gut microbiota (such as promoting the proliferation of Bifidobacterium) and directly regulating the host immune system. 1,4-Dihydroxy-2-naphthoic acid induces apoptosis through G0/G1 cell cycle arrest in human keratinocyte to inhibit psoriasis .

Cat. No.	상품명	Chemical Structure

HY-17355S1

Pramipexole-d5 dihydrochloride

Pramipexole-d₅ dihydrochloride is deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-17355S

Pramipexole-d7 dihydrochloride

Pramipexole-d₇ dihydrochloride is the deuterium labeled Pramipexole dihydrochloride. Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-B0410S1

Pramipexole-d5
Pramipexole-d₅ is the deuterium labeled Pramipexole . Pramipexole is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

HY-A0007S

Rotigotine-d7 hydrochloride

Rotigotine-d₇ (N-0923-d₇) hydrochloride is the deuterium labeled Rotigotine(HY-75502). Rotigotine is a potent dopamine receptor agonist with K_i values of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors and dopamine D1 receptor. Rotigotine a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor. Rotigotine can be used for parkinson's disease (PD) research.

HY-17355S2

Pramipexole-d7-1 dihydrochloride

Pramipexole-d₇-1 dihydrochloride is the deuterium labeled Pramipexole dihydrochloride . Pramipexole dihydrochloride is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with K_is of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS) .

Cat. No.	상품명		Classification